PALVELLA THERAPEUTICS, INC.
PVLANasdaqHealthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $38.7M | $25.5M | $27.9M | $23.9M |
| Operating income | −$38.6M | −$14.1M | −$29.8M | −$43.5M | −$51.8M | −$33.9M |
| Net income | −$41.7M | −$17.4M | −$24.5M | −$33.3M | −$45.7M | −$37.2M |
| Total assets | $59.6M | $88.2M | $38.7M | $95.5M | $153.6M | $105.0M |
| Total liabilities | $31.6M | $25.6M | $11.9M | $67.6M | $102.8M | $74.0M |
| Equity | $28.0M | $62.6M | $26.8M | $27.9M | $50.8M | $31.0M |
| EPS (diluted) | $-3.71 | $-7.83 | $2.17 | $-0.45 | $-0.71 | $-0.68 |
| Shares out. | 11.0M | 98.9M | 74.5M | 74.1M | 59.7M | 55.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −149.1%
- Return on assets
- −70.0%
- Return on capital (ROCE)
- −80.1%
- Liabilities / assets
- 53.0%
- Debt / equity
- 1.13×
- Book value / share
- $2.54
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -5.59distress
- Accruals / assets
- −28.1%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2023-10A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
- Phase 2Active Not Recruitingreadout ~2025-11-21A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
- Phase 3Active Not Recruitingreadout ~2026-01-14SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
- Phase 2Recruitingreadout ~2027-08A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- First Light Asset Management, LlcPassive (13G)Feb 17, 2026
- Biotechnology Value Fund L PPassive (13G)Feb 17, 2026
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Feb 13, 2026
- Suvretta Capital Management, LlcPassive (13G)Nov 13, 2025
- Samsara Biocapital, L.P.Passive (13G)Aug 14, 2025
- Kaupinen WesActivist (13D)Dec 20, 2024
- Dellora Investments LpPassive (13G)Dec 17, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Goin KathleenOfficer — Chief Operating Officer | May 20, 2026 | Option exercise | 2,154 | $7.14 |
| Goin KathleenOfficer — Chief Operating Officer | Apr 15, 2026 | Option exercise | 2,154 | $7.14 |
| Jenkins George MDirector | Mar 30, 2026 | Buy | 445 | $112.30 |
| Goin KathleenOfficer — Chief Operating Officer | Mar 18, 2026 | Option exercise | 2,154 | $7.14 |
| Jenkins George MDirector | Feb 27, 2026 | Buy | 4,000 | $125.00 |
| Heron Elaine JDirector | Feb 27, 2026 | Buy | 2,400 | $125.00 |
| Goin KathleenOfficer — Chief Operating Officer | Feb 18, 2026 | Option exercise | 2,154 | $7.14 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.1M | 8.9 | -1.1% |
| Apr 30, 2026 | 2.2M | 10.7 | +9.7% |
| Apr 15, 2026 | 2.0M | 8.2 | -9.1% |
| Mar 31, 2026 | 2.2M | 7.5 | +12.8% |
| Mar 13, 2026 | 1.9M | 6.8 | +10.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 20, 2026
- Other material eventMay 15, 2026
- Other material eventMay 13, 2026
- Results of operations · Regulation FD disclosureMay 7, 2026
- Director / officer changeApr 13, 2026
- Other material eventApr 7, 2026
- Results of operations · Regulation FD disclosureMar 31, 2026
- Entered a material agreementFeb 26, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4OWNERSHIP DOCUMENTMay 22, 2026
- 144May 20, 2026
- 8-KMay 20, 2026
- 8-KMay 15, 2026
- 8-KMay 13, 2026
- 8-KMay 7, 2026
- 10-QMay 7, 2026
- ARSApr 30, 2026
- DEFA14AApr 30, 2026
- DEF 14AApr 30, 2026
- 4OWNERSHIP DOCUMENTApr 17, 2026
- 4OWNERSHIP DOCUMENTApr 15, 2026
- 3OWNERSHIP DOCUMENTApr 15, 2026
- 144Apr 15, 2026
- 8-KApr 13, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.